Sign in
ACLX Stock Price, Chart, Stats & News
Arcellx, Inc.
Save
6.73B
Market cap
–
Current P/E
61.73x
Forward P/E
ACLX chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | -64.81% |
Operating margin | -1135.61% |
Pretax margin | -1026.95% |
Net margin | -1027.25% |
Effective tax rate | -0.03% |
ROA | -37.90% |
ROE | -55.42% |
D/E | 0.24x |
Interest coverage ratio | -10.45x |
ACLX valuation
P/E | – |
P/S | 300.64x |
P/B | 16.03x |
P/CF | -30.68x |
P/FCF | -31.52x |
P/OCF | -30.68x |
PEG | 8.54x |
EV multiple | -33.76x |
About
Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering immunotherapeutic solutions for patients battling cancer and other intractable diseases. A cornerstone of their pipeline is CART-ddBCMA, an advanced ddCAR product candidate currently undergoing a Phase 1 clinical trial. This investigational treatment targets individuals suffering from relapsed or refractory multiple myeloma (MM).
Similar securities
Based on sector and market capitalization
Report issue